Healthcare / Medical Instruments & SuppliesTokyo
$27495.00
+1190.00 (+4.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $181.7B · quality 85.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.20T
P/E
36.9x
↑EV/EBITDA
29.2x
↑ROE
20.7%
↑Gross Margin
86.5%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
+5.1%
FCF margin
21.1%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $885.82B · net income $202.10B · FCF $187.19B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $885.82B | $885.82B | $792.63B | $734.10B | $670.33B |
| Net Income | $202.10B | $202.10B | $181.38B | $168.64B | $164.51B |
| EBITDA | $310.00B | $310.00B | $285.70B | $267.26B | $255.39B |
| EPS | — | — | 515.27 | 469.47 | 445.93 |
| Gross Margin | 86.5% | 86.5% | 86.8% | 86.1% | 84.6% |
| Operating Margin | 54.3% | 54.3% | 54.7% | 54.6% | 54.2% |
| Net Margin | 22.8% | 22.8% | 22.9% | 23.0% | 24.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
| Current Ratio | 4.81 | 4.81 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $187.19B | $187.19B | $181.73B | $168.36B | $161.18B |
| Returns | |||||
| ROE | 20.7% | 20.7% | 18.7% | 20.6% | 20.5% |
| Valuation | |||||
| P/E | 36.93 | 36.93 | 33.82 | 30.13 | 31.40 |
| EV/EBITDA | 29.24 | 29.24 | 19.73 | 17.58 | 18.46 |
| P/B | 9.81 | 9.81 | 6.34 | 6.21 | 6.36 |
| Growth & Yield | |||||
| Revenue Growth | 11.8% | 11.8% | 8.0% | 9.5% | — |
| EPS Growth | — | — | 9.8% | 5.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.7%
Start / end P/E
n/dx → n/dx
EPS bridge
515.27 → n/d
Residual
+56.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.